Uveal metastasis from nonsmall cell lung carcinoma with dramatic response to erlotinib Journal Article


Authors: Daniels, A. B.; Miller, M. L.; Kotecha, A.; Abramson, D. H.
Article Title: Uveal metastasis from nonsmall cell lung carcinoma with dramatic response to erlotinib
Abstract: Purpose: To report the case of a never-smoker patient whose initial presentation of metastatic nonsmall cell lung carcinoma was with uveal metastasis, which had a dramatic response to targeted biologic therapy with erlotinib (Tarceva) after failing conventional chemotherapy. Methods: Case report. A 43-year-old man with uveal metastasis from nonsmall cell lung adenocarcinoma. Results: After failing conventional chemotherapy with carboplatin and taxol, with continued documented rapid growth of the uveal metastasis, treatment was initiated with the targeted biologic agent, erlotinib, which is a protein tyrosine kinase inhibitor of the epidermal growth factor receptor(EGFR). Within 3 days of starting erlotinib, shrinkage of the choroidal lesion was noted, and over the course of the next 3 months, the tumor completely and durably disappeared, with vision improving from hand motion to 20/25. The patient is still alive and well after 3 years, on continued daily oral erlotinib treatment. Conclusion: Erlotinib is a well-tolerated newly available Food and Drug Administration- approved oral targeted biologic agent, which may be beneficial in some patients with uveal metastasis from nonsmall cell lung carcinoma, in which an underlying epidermal growth factor receptor mutation is suspected. © by ophthalmic Communications Socity, Inc.
Keywords: erlotinib; epidermal growth factor receptor; protein kinase inhibitors; neoplasm metastasis; choroid; uveal neoplasms; nonsmall cell lung carcinoma; tarceva
Journal Title: Retinal Cases and Brief Reports
Volume: 4
Issue: 4
ISSN: 1935-1089
Publisher: Ophthalmic Communications Society, Inc  
Date Published: 2010-01-01
Start Page: 390
End Page: 393
Language: English
DOI: 10.1097/ICB.0b013e3181e180e6
PROVIDER: scopus
DOI/URL:
Notes: --- - "Export Date: 3 October 2011" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. David H Abramson
    389 Abramson